缬沙坦联合前列地尔治疗慢性肾小球肾炎患者的临床研究  

Clinical trial of valsartan combined with alprostadil in the treatment of patients with chronic glomerulonephritis

作　　者：张云[1] 施书涵[1] 车丽双 林威远[1] ZHANG Yun;SHI Shu-han;CHE Li-shuang;LIN Wei-yuan(Department of Nephrology,the Second Affiliated Hospital of Fujian Medical University,Quanzhou 362000,Fujian Province,China)

机构地区：[1]福建医科大学附属第二医院肾脏内科,福建泉州362000

出　　处：《中国临床药理学杂志》2020年第12期1614-1616,共3页The Chinese Journal of Clinical Pharmacology

基　　金：泉州市科技计划基金资助项目(2018Z125)。

摘　　要：目的观察缬沙坦联合前列地尔治疗慢性肾小球肾炎患者的临床疗效,及其对患者肾功能和血流动力学的影响。方法将我院收治的慢性肾小球肾炎患者120例,随机分为试验组和对照组,各60例。对照组给予缬沙坦,每次80 mg,每天1次,清晨口服;试验组在对照组的基础上给予前列地尔10μg,注入0.9%NaCl溶液100 mL中,每天1次,静脉滴注。2组均连续治疗6周。检测2组患者治疗前后全血高切黏度、全血低切黏度、血浆黏度、血小板聚集率和红细胞聚集指数;同时检测患者的尿素氮(BUN)、血肌酸酐(SCr)与24 h尿蛋白水平。观察治疗过程中的药物不良反应发生情况。结果治疗后,对照组与试验组血清BUN水平分别为(5.72±1.61),(4.61±1.56)mmol·L^-1;血清SCr水平分别为(118.90±16.62),(105.20±17.57)μmol·L^-1;24 h尿蛋白分别为(1.12±0.19),(0.84±0.25)g。治疗后,2组全血高切黏度、全血低切黏度、血浆黏度、血小板聚集率和红细胞聚集指数、BUN、SCr水平及尿液24 h尿蛋白均较治疗前降低,且试验组低于对照组(均P<0.05)。2组药物不良反应发生率差异无统计学意义(P>0.05)。结论缬沙坦联合前列地尔用于慢性肾小球肾炎的治疗,能有效改善患者肾功能和患者的血流动力学指标。Objective To analyze the clinical efficacy of valsartan combined with alprostadil in the treatment of patients with chronic glomerulonephritis, and its effect on renal function and hemorheology. Methods A total of 120 patients with chronic glomerulonephritis in our hospital were randomly divided into treatment group and control group, 60 patients in each group. Control group was treated with valsartan 80 mg, once a day,oral in the early morning. Treatment group was treated with alprostadil 10 μg, dissolved into 0.9%NaCl 100 mL, once a day, intravenous drip on the basis of control group. Two groups were all treated for 6 weeks. The whole blood high shear viscosity, whole blood low shear viscosity, plasma viscosity, platelet aggregation rate, red blood cell aggregation index, urinary nitrogen(BUN), serum creatinine(SCr) and 24 h urine protein(24 h Upro) in two groups were observed before and after treatment. Results After treatment, the BUN levels in control group and treatment group were(5.72±1.61),(4.61±1.56) mmol·L-1;SCr levels were(118.90±16.62),(105.20±17.57) μmol·L-1;24 h Upro were( 1. 12 ± 0. 19),( 0. 84 ± 0. 25) g. After treatment,whole blood high shear viscosity,whole blood low shear viscosity,plasma viscosity and erythrocyte aggregation index,platelet aggregation rate,BUN,SCr levels and 24 h Upro in two groups were decreased compared with before treatment;and treatment group were lower than control group( all P < 0. 05). There was no significant difference in the incidence of adverse drug reactions between the two groups( P > 0. 05). Conclusion Valsartan combined with alprostadil can effectively improve renal function and hemorheology in the treatment of chronic glomerulonephritis patients.

关 键 词：缬沙坦 前列地尔 肾小球肾炎 血流动力学 

分 类 号：R97[医药卫生—药品]